Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Mount Medical Centre, Perth
Alzheimer disease analyzed, presenilin immunoreactivity detected
October 26th, 2005
A study from Australia has documented presenilin (PS) immunoreactivity in Alzheimer disease (AD). "The role of PS mutations in familial AD may be as a toxic gain of function, but in sporadic disease their contribution is more difficult to understand," wrote P.K. Panegyres and colleagues, Mount Medical Centre. "In this study, we investigated PS proteins in sporadic AD by comparing the immunocytochemical profiles in sporadic AD with control brains using a quantitative immunocytochemical approach to both the N- and C-terminals of PS1 and PS2. "Ten patients with pathologically proven AD (using modified Consortium to Establish a...
Source: Elder Law Weekly (2005-10-26)
|
